pimavanserin brands

Molecular formula: C25H34FN3O2

Parkinson's disease psychosis (PDP) is an imbalance of serotonin and dopamine from disruption of the normal balance between the serotonergic and dopaminergic receptors and neurotransmitters in the brain. The mechanism by which pimavanserin treats hallucinations and delusions associated with Parkinson’s disease psychosis is not fully established. It is possible that pimavanserin acts via inverse agonist and antagonist activity at serotonin 5-HT_2A receptors with limited effects on serotonin 5-HT_2C receptors. Pimavanserin is an inverse agonist and antagonist of serotonin 5-HT_2A receptors with high binding affinity, demonstrating low binding affinity to serotonin 5-HT_2C receptors. In addition, this drug exhibits low affinity binding to sigma 1 receptors. Pimavanserin lacks activity at muscarinic, dopaminergic, adrenergic, and histaminergic receptors, preventing various undesirable effects typically associated with antipsychotics.

Source: PubChem (NCBI) · compound 10071196